Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

AstraZeneca Reports Higher Profits, But Cuts R&D Jobs

28 Jan 2010

• By The Pink Sheet Daily

AstraZeneca's patent expiry woes clear amid disappointing '09 results.

Related Content

Pfizer's Message To Wall Street: We're Doing Things Differently Now

11 Jan 2010

AstraZeneca Takes Out Antibiotic Firm Novexel, With Cash Back from Forest

23 Dec 2009

Eli Lilly Hires AstraZeneca's Jan Lundberg To Replace Steve Paul As Head Of R&D

13 Nov 2009

AstraZeneca Sees Emerging Market Opportunity for Forest Anti-Infective

12 Aug 2009

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2024 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.